Related Experiment Video
Updated: Jul 3, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead
Haoran Wang1,2,3, Yuping Chen4,5, Xinshu Wang5
1Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Purpose:
The incidence of multiple primary malignancies (MPM) involving lung cancer has increased in recent decades. There is an urgent need to clarify the genetic profile of such patients and explore more efficacious therapy for them.
Experimental Design:
Peripheral blood samples from MPM involving patients with lung cancer were assessed by whole-exome sequencing (WES), and the identified variants were referenced for pathogenicity using the public available database. Pathway enrichment analysis of mutated genes was performed to identify the most relevant pathway. Next, the effects of mutations in relevant pathway on function and response to targeted drugs were verified by in vitro and in vivo experiments.
Results:
Germline exomes of 71 patients diagnosed with MPM involving lung cancer were sequenced. Pathway enrichment analysis shows that the homologous recombination repair (HRR) pathway has the strongest correlation. Moreover, HRR genes, especially key Holliday junction resolvases (HJR) genes (GEN1, BLM, SXL4, and RMI1), were most frequently mutated, unlike the status in the samples from patients with lung cancer only. Next, we identified a total of seven mutations in HJR genes led to homologous recombination DNA repair deficiency and rendered lung cancer cells sensitive to PARP inhibitor treatment, both in vitro and in vivo.
Conclusions:
This is the first study to map the profile of germline mutations in patients with MPM involving lung cancer. This study may shed light on early prevention and novel targeted therapies for MPM involving patients with lung cancer with HJR mutations.
Insights
Multiple primary lung cancers are increasing. We found specific gene mutations in the homologous recombination repair pathway, suggesting new targeted therapies like PARP inhibitors for these patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The incidence of multiple primary malignancies (MPM) involving lung cancer is rising.
- Clarifying the genetic landscape of these patients is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the germline genetic profile of patients with MPM involving lung cancer.
- To identify potential therapeutic targets for this patient population.
Main Methods:
- Whole-exome sequencing (WES) of germline DNA from 71 MPM patients with lung cancer.
- Pathway enrichment analysis to identify significantly mutated pathways.
- In vitro and in vivo experiments to validate the functional impact of mutations and drug sensitivity.
Main Results:
- Homologous recombination repair (HRR) pathway genes were frequently mutated in MPM lung cancer patients.
- Specific mutations in Holliday junction resolvase (HJR) genes (GEN1, BLM, SXL4, RMI1) were identified.
- These HJR mutations led to DNA repair deficiency and sensitivity to PARP inhibitors in lung cancer cells.
Conclusions:
- This study provides the first comprehensive germline mutation profile for MPM involving lung cancer.
- Identified HJR mutations and HRR pathway alterations may guide early prevention strategies.
- Findings suggest potential for novel targeted therapies, including PARP inhibitors, for MPM lung cancer patients with HJR mutations.
More Related Videos
Related Concept Videos
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Prevention
Some...
Cancers Originate from Somatic Mutations in a Single Cell
Abnormal Proliferation

